Catalyst Calendar
Scope

Mon, Jun 29, 2026

1 updates
RGNX
7:05 AM

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Society of Retina Specialists (ASRS) 2026 ROCKVILLE, Md., June 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE

Trial Start • Phase 2/3Trial initiation Mon, Jun 29, 2026, 7:05 AM EDTregenxbio.com

Wed, Jun 24, 2026

1 updates

Mon, Jun 22, 2026

1 updates

Mon, May 18, 2026

1 updates
RGNX
4:05 PM

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: 2026 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 20 at 9:30am ET Location: New York, NY Stifel 2026 Virtual

regenxbio.com

Thu, May 14, 2026

2 updates
RGNX
7:10 AM

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

Company announced positive topline results from pivotal Phase III AFFINITY DUCHENNE ® study of RGX-202 Primary endpoint achieved with high statistical significance Statistically significant correlation between RGX-202 microdystrophin expression and functional improvement (NSAA, n=9), supporting

Trial Results • Phase 3Topline results Thu, May 14, 2026regenxbio.com

Thu, May 7, 2026

1 updates

Wed, May 6, 2026

1 updates